Subscribe / Renew |
|
Contact Us |
|
► Subscribe to our Free Weekly Newsletter |
home | Welcome, sign in or click here to subscribe. | login |
print email to a friend reprints add to mydjc |
March 10, 2022
Seattle-based AVM Biotechnology, a clinical stage company developing cancer drug AVM0703, announced the appointment of Brian Andersen as chief commercial officer and Pearl Chan as chief financial officer. They will help drive the company towards anticipated commercialization in 2023. Andersen brings over 20 years of commercial experience as a corporate executive, and has experience building companies, launching new products, developing specialty pharmacy distribution networks with patient support programs, as well as generating and executing marketing plans. He has spent most of his career in the hospital, orphan disease and oncology areas of the pharmaceutical and biotech industry, cofounding Vidara Therapeutics and working for companies such as Pharmacia, Dendreon and Horizon Therapeutics. Chan has 25 years of financial leadership experience in the tech industry having built high-performing teams as CFO at PicMonkey and NetMotion Software. These additions to the leadership team are timed with the near completion of the safety portion of a clinical trial in treating “no-option” Non-Hodgkin's Lymphoma/Leukemia patients.